Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGN7508 for Prevention of Venous Thromboembolism After Elective, Unilateral, Total Knee Arthroplasty
NCT06454630Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2024
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of REGN7508 in venous thromboembolism (VTE), sponsored by Regeneron Pharmaceuticals. Started Jun 2024; status: completed.
02
Drugs
REGN7508
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06454630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06454630.